In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi’s CAD drug Enjaymo

Fierce Pharma October 4, 2024
Fraiser Kansteiner

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action.

Recordati is floating $825 million upfront—plus another $250 million in potential commercial milestones—to get its hands on the global rights to Sanofi’s rare disease biologic Enjaymo.

In 2022, Enjaymo became the first and only therapy specifically approved by the FDA for the treatment of hemolysis, or the destruction of red blood cells, in patients with the uncommon blood disorder cold agglutinin disease (CAD). That same year, Sanofi’s C1 inhibitor also scored CAD green lights in Europe and Japan, Recordati noted in a press release Friday.

The deal is expected to close by the end of 2024, which means Recordati is unlikely to see...

Today's Sponsors

Today's Sponsor